12:00 AM
Oct 19, 2015
 |  BC Week In Review  |  Company News  |  Other News

Alexza drug delivery, neurology news

Alexza retained Guggenheim Securities to explore strategic options, including the sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Alexza’s Adasuve loxapine --...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >